US radioisotope supplier TAG1 and Netherlands-based nuclear solutions company NRG Pallas have signed a letter of intent (LOI) to jointly advance access to lead-212 (Pb-212) for the development of next-generation cancer therapies across Europe.

The agreement builds on an existing supply arrangement under which NRG Pallas will continue to deliver high-purity Radium-224 (Ra-224) to TAG1 until 2028.

Together, TAG1 and NRG Pallas will work to deliver pre-clinical and clinical quantities of Pb-212 to cancer drug innovators across Europe, including pioneering therapeutic companies and hospital-based adult and paediatric oncology programmes.